Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $25,793.04 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 30,706 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $25,793.04. Following the completion of the sale, the insider owned 283,774 shares in the company, valued at $238,370.16. The trade was a 9.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Monday, August 17th, Jill Andersen sold 37,256 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32.

Invivyd Trading Down 0.9%

Shares of IVVD stock opened at $0.95 on Friday. The company has a market cap of $280.26 million, a P/E ratio of -2.88 and a beta of 0.71. The firm has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.22. Invivyd, Inc. has a 12 month low of $0.48 and a 12 month high of $3.07.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. On average, equities analysts forecast that Invivyd, Inc. will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new stake in Invivyd during the 2nd quarter worth $30,048,000. Perceptive Advisors LLC acquired a new position in Invivyd in the fourth quarter valued at $53,809,000. BVF Inc. IL acquired a new position in Invivyd in the fourth quarter valued at $48,227,000. RA Capital Management L.P. purchased a new stake in shares of Invivyd in the third quarter valued at about $18,831,000. Finally, BlackRock Inc. purchased a new stake in shares of Invivyd in the second quarter valued at about $14,076,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.